Irbesartan/Amlodipine: A Review of its Use in Adult Patients with Essential Hypertension Not Adequately Controlled with Monotherapy
In: American Journal of Cardiovascular Drugs, Jg. 13 (2013-03-21), S. 141-150
Online
unknown
Zugriff:
Combination therapy is often required in patients with hypertension, and fixed-dose single-pill combinations have been shown to provide an easier regimen for patients, improving adherence. Irbesartan/amlodipine (Aprovasc®) is an angiotensin-receptor blocker/calcium-channel blocker fixed-dose single-pill combination, whose constituent drugs exert additive effects when coadministered. In two randomized, open-label, multicentre, phase III trials, fixed-dose combination therapy with irbesartan/amlodipine was more effective than continuation of irbesartan or amlodipine monotherapy in patients with hypertension not adequately controlled with initial irbesartan or amlodipine monotherapy; there was a significantly greater decrease from baseline in mean seated home systolic blood pressure (primary endpoint) with the fixed-dose combination. The fixed-dose combination was also associated with a greater decrease in mean seated home diastolic blood pressure and mean seated office systolic and diastolic blood pressure than monotherapy. The fixed-dose combination of irbesartan/amlodipine was well tolerated in these patients; most treatment-emergent adverse events were of mild or moderate severity. The most frequent adverse event was peripheral oedema, generally associated with amlodipine treatment.
Titel: |
Irbesartan/Amlodipine: A Review of its Use in Adult Patients with Essential Hypertension Not Adequately Controlled with Monotherapy
|
---|---|
Autor/in / Beteiligte Person: | Garnock-Jones, Karly P. |
Link: | |
Zeitschrift: | American Journal of Cardiovascular Drugs, Jg. 13 (2013-03-21), S. 141-150 |
Veröffentlichung: | Springer Science and Business Media LLC, 2013 |
Medientyp: | unknown |
ISSN: | 1179-187X (print) ; 1175-3277 (print) |
DOI: | 10.1007/s40256-013-0014-7 |
Schlagwort: |
|
Sonstiges: |
|